Alergenový provokační test IRL201104 u sezónní alergické rýmy
Fáze 2a, randomizovaná, dvojitě zaslepená, placebem kontrolovaná, paralelní design, alergenová provokační zkouška 6 opakovaných dávek IRL201104 u dospělých účastníků se sezónní alergickou rýmou.
The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
London, Spojené království
- Hammersmith Medicines Research
-
London, Spojené království
- King's College London
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Male or female, 18 to 65 years old, inclusive, at time of signing the informed consent form (ICF).
-
Body mass index within the range 19 to 30 kg/m2.
-
A clinical history of grass pollen-induced allergic rhinitis for at least 2 years with peak symptoms in May, June, or July.
-
A clinical history of moderate to severe rhinitis symptoms interfering with usual daily activities or with sleep as defined according to the ARIA classification of rhinitis (Bousquet, Khaltaev et al 2008)
-
A clinical history of rhinitis for at least 2 years requiring treatment with either antihistamines or nasal corticosteroids during the grass pollen season.
-
Positive skin prick test response, defined as wheal diameter greater than or equal to 5 mm, to Phleum pratense.
-
Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L), against Phleum pratense.
-
A positive response to the nasal allergen challenge with Phleum pratense, defined as an increase in TNSS greater than or equal to 5 points.
-
Agree to follow the contraception requirements of the trial as described in Appendix 7.
Female participants must agree to use highly effective contraception as described in Appendix 7, or must be of non-childbearing potential. A woman is considered to be of non-childbearing potential if she meets one of the following criteria:
- post-menopausal (amenorrhea for at least 12 months, and follicle-stimulating hormone [FSH] tests at screening confirms post-menopausal status)
- has no uterus, ovaries or fallopian tubes. c. documentation of non-childbearing potential from a reproductive specialist.
-
The ability to give informed consent and comply with study procedures.
-
Venous access as appropriate for IV dosing, as judged by the investigator or delegate.
Exclusion Criteria:
- A prebronchodilator forced expiry volume in 1 second (FEV1) less than 70% of the predicted value at the screening baseline visit.
- Clinical history of persistent asthma requiring regular inhaled corticosteroids for > 4 weeks per year outside of the grass pollen season.
- Clinical history of moderate - severe allergic rhinitis, according to the ARIA classification, caused by a perennial allergen to which the participant is regularly exposed.
- Clinical history of moderate-severe allergic rhinitis, according to the ARIA classification, caused by tree pollen (those with mild intermittent symptoms not requiring regular treatment may be included).
- History of emergency visit or hospital admission for asthma in the previous 12 months.
- History of chronic obstructive pulmonary disease.
- History of significant recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment.
- History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, ear pain, pressure, or fullness.
- History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency.
- At randomization, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media, or other relevant infectious process; serous otitis media is not an exclusion criterion. Participants may be re-evaluated for eligibility after symptoms resolve.
- Active malignancy at randomization.
- Any tobacco smoking within the last 6 months or a history of greater than or equal to 10 pack years.
- Previous treatment by immunotherapy with grass pollen allergen within the previous 5 years.
- History of bleeding disorders or treatment with anticoagulation therapy.
- History of anti-IgE monoclonal antibody treatment.
- Ongoing systemic immunosuppressive treatment.
- History of intolerance to the study therapy, rescue medications, or their excipients.
- Pregnant or lactating women. For women of childbearing potential, a positive serum or urine pregnancy test.
- The use of any investigational drug within 30 days of the screening visit.
- The presence of any medical condition that the investigator deems incompatible with participation in the study.
- Moderate or severe renal impairment (eGFR <60 mL/min/1.73 m2) or end stage renal disease.
23. Known or suspected immunosuppression, including history of invasive opportunistic infections (eg, history of or active tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immunocompromised status, as judged by the investigator. 24. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the volunteer. 25. Clinical contraindication to intradermal challenge (IDC), skin prick test (SPT), skin prick titration (SPT), or nasal allergen challenge (NAC), to include:
- Previous anaphylactic reaction to grass pollen or extract excipients
- Acute inflammation of the nose or paranasal sinuses
- Severe and uncontrolled bronchial asthma or chronic obstructive pulmonary disease
- Systemic immunotherapy
- A generalised dermatological condition rendering it impracticable to perform SPT or IDC on unaffected skin.
- Severe dermatographism
- Unable to cease antihistamines/other interfering drugs (i.e. antidepressants)
- Concomitant use of beta-blockers
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Arm 1: IRL201104
IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70 |
lyophilised powder for reconstitution for IV dosing |
|
Komparátor placeba: Arm 2: Placebo
Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70 |
Matching placebo for IRL201104 |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The mean diameter of the Intradermal Challenge (IDC) Late Phase Response (LPR) on Day 84 measured 8 hours post-challenge after 10 weeks of treatment with IRL201104 compared with placebo.
Časové okno: Day 84
|
An analysis of covariance (ANCOVA) will be performed |
Day 84
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The largest diameter (mm) of the IDC Early Phase Response (EPR) at 30 minutes after 10 weeks of treatment with IRL201104 compared with placebo
Časové okno: Day 84
|
An analysis of covariance (ANCOVA) will be performed |
Day 84
|
|
Skin prick test EPR endpoint titration of Grass Soluprick after 10 weeks of treatment with IRL201104 compared with placebo.
Časové okno: Day 84
|
An analysis of covariance (ANCOVA) will be performed |
Day 84
|
|
The weighted average of the TNSS per hour following NAC after challenge on Day 1 and day 84 of treatment with IRL201104 compared with placebo.
Časové okno: Day 84
|
An analysis of covariance (ANCOVA) will be performed |
Day 84
|
|
Percent change in peak nasal inspiratory flow (PNIF) after the NAC on day 1 and day 84 of treatment with IRL201104 compared with placebo.
Časové okno: Day 84
|
An analysis of covariance (ANCOVA) will be performed |
Day 84
|
|
Concentration of IRL20114 levels.
Časové okno: Day 56
|
IRL201104 plasma levels will be summarized for each blood sample draw timepoint |
Day 56
|
|
Vital Signs: Blood pressure
Časové okno: Day 84
|
Summary statistics, by and across randomized treatment group |
Day 84
|
|
Vital Signs: Pulse rate
Časové okno: Day 84
|
Summary statistics, by and across randomized treatment group |
Day 84
|
|
Vital Signs: oral body temperature
Časové okno: Day 84
|
Summary statistics, by and across randomized treatment group |
Day 84
|
|
Vital Signs: respiration rate
Časové okno: Day 84
|
Summary statistics, by and across randomized treatment group |
Day 84
|
|
Treatment Emergent Adverse Events
Časové okno: Day 84
|
Summary statistics, by and across randomized treatment group |
Day 84
|
|
Incidence of treatment-emergent antidrug antibody (ADA) responses
Časové okno: Day 84
|
Tabulated and presented as the number and percentage of participants exhibiting the response within each treatment group |
Day 84
|
|
Safety Laboratory: Biochemistry
Časové okno: Day 84
|
Glucose, liver function tests, urea, and electrolytes will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84. |
Day 84
|
|
Safety Laboratory: Haematology
Časové okno: Day 84
|
Full blood count variables will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84. |
Day 84
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Anoshie Ratnayake, MD, Revolo Biotherapeutics
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- RVLO 121-05
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .